Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
- 1 February 2004
- journal article
- research article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 8 (5)
- https://doi.org/10.3310/hta8050
Abstract
Health Technology Assessment Volume: 8, Issue: 5, Published in February 2004Keywords
Funding Information
- Health Technology Assessment Programme (01/57/01)